P resbyacusis, or age-related hearing loss (HL), is a prevalent medical problem in older adults 1 that has been found to be associated with perceived problems in access to medical care, 2 negative life events such as incident dementia, 3, 4 higher rates of falls, 5 poorer cognitive functioning, 6 higher risk of death in men, 7 poorer healthrelated quality of life, [8] [9] [10] and social isolation.
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HL is among the most common chronic conditions of aging, with 26.2 million individuals aged 50 and older reporting HL. 3 HL is estimated to affect 63% of the Medicare eligible population aged 70 and older, 1 but only approximately 17% of older U.S. adults with HL use hearing aids. 12 Given these statistics, we might expect HL to be defined as an important public health problem and the target of efforts to improve population health, particularly in view of the projected increases in the aging population, but Healthy People 2020, which identifies the U.S. nationwide health improvement priorities, reports for 2007 that only 162.7 individuals per 1,000 people aged 20 to 69 with HL had ever used a hearing aid. 13 The stated 2020 goal is to increase this rate to 179 per 1,000 individuals by 2020 13 -an increase of 0.8% per year, indicating that this condition is not a high priority target for the nation's health. It is possible that HL in older adults is so common that it is not perceived as a problem or is simply considered a normal consequence of aging that requires diagnosis and intervention only if the individual requests it. An alternative view is that decision-makers, such as payors, legislatures, and providers, have a pervasive and persistent lack of understanding of the potential broader health ramifications of HL.
Identification of associations between HL and medical care use is an important health policy step for reclassifying HL from a "condition" to that of a "problem" in the minds of U.S. health policy-makers. This is an essential step for policy changes aimed at increasing awareness of HL and the need for better identification of individuals with HL and improving access to and use of hearing healthcare services.
HL has been associated with social isolation in older adults 11 and frustration. 9 Recent evidence indicates that individuals with HL have significantly higher odds of rating their satisfaction with communication with their physicians below the median (doctor explained things clearly, listened carefully, showed respect for what they had to say, afforded them adequate time) and were less likely to rate the overall quality of their healthcare above the median. 14 People with HL may feel dissatisfied with communication with their physician and may choose not to make medical visits because they are stressful and frustrating. 15, 16 This is an important satisfaction concern that may become an access-to-care barrier. 17 Less-timely healthcare-seeking behavior could lead to a longer time between visits and exacerbate healthcare conditions. 18 These gaps in care may result in increases in use of moreacute, more-expensive healthcare services, resulting in higher healthcare costs. 18 Few studies have examined healthcare cost differences according to HL. To begin to measure the effect of HL on overall healthcare use, our group recently published a cost and usage study of middle-aged privately insured adults that found 33% higher average healthcare services costs over 18 months in a well-matched group of individuals with HL as compared to those without HL. 19 To examine whether similar results may be found in an older publically insured population, the current study compared the average healthcare costs of a U.S. sample of older adults with and without HL matched on all potential and available cost risk factors and chronic diseases.
METHODS
We extracted information on 2 cohorts of individuals aged 65 and older with an International Classification of Diseases, Ninth Revision (ICD-9) code fo HL (V41. 22 Matching was based on the nearest-neighbor greedy-matching algorithm without caliper distance limits and without replacement. 23 Goodness of match was examined and confirmed for each matched cohort by statistically comparing all matching characteristics using descriptive statistics and with standardized differences in means and proportions of each matching variable being less than 0.2. 24 Six months of lookback period data were used for each individual to develop the baseline variables for matching. Individuals with diagnoses of late effects of stroke, coma, or paralysis were excluded. Healthcare bills for up to 18 months postbaseline follow-up were summed according to participant to calculate total payments for inpatient, outpatient, prescription medication, and hearing services. Hearing services were defined as ICD-9 procedure codes 9548, 69710, 69711, V532, V5014, V5267, V5298, V5010, V5011, or V5275 (Supplementary Table S2 ).
Statistical Analysis
Descriptive statistics and crude outcome estimates for the HL and comparison groups were compared using chi-square tests for categorical variables and t-tests (normally distributed) or Mann-Whitney U-or Wilcoxon tests (nonnormally distributed) for continuous variables. P-values for descriptive statistics are not shown because sample sizes were so large as to result in statistically significant differences even if they were not clinically important. Differences between matched groups were tested using standardized differences in means or proportions.
Outcomes analysis for total payments and payment type subgroups were compared according to group using gamma-distributed generalized linear log-linked multivariable regression models, adjusting for baseline covariates. The use of a gamma-distributed generalized linear model with a log-transformed link function has been shown to be a good was to estimate healthcare cost distributions that are generally right skewed, especially when the logtransformed dependent variables do not have heavy tails or excessive heteroscedasticity. 25 Adjustors considered for inclusion in each outcome model include demographic characteristics, chronic conditions, Charlson Comorbidity Index score, number of days in the follow-up period, and use of hearing services. Variables removed from the final models included only those with little to no predictive or confounding effect and no influence on model fit (Akaike Information Criterion) or primary estimate (beta), which resulted in final models including all covariates except the rarer chronic conditions (multiple sclerosis, schizophrenia, human immunodeficiency virus, cystic fibrosis, sickle cell anemia). 26 Sensitivity analyses to assess the effect of hidden bias for each outcome were performed using previously defined methods 27 that provide a way to quantify the robustness of the results when potential selection bias due to unmeasured confounders is simulated. SAS version 9.4 (SAS Institute, Inc., Cary, NC) was used for analysis with p-values considered statistically significant for a<.05. The Medical University of South Carolina institutional review board reviewed the study protocol and deemed that it constituted nonhuman research.
RESULTS
Members of Cohort 1 had an average age of 7667.8, had low comorbidity, and were split evenly between men and women in the HL and no-HL groups (Table 1) . Just over 28% of Cohort 1 members with HL received hearing services (Table 1) . This cohort had the lowest proportion of chronic illnesses of the 3 groups. The matched Cohort 2 had an average age of 77 and was 61.1% female and 89% white ( Table 1) . Members of Cohort 2 with HL included only 3.8% of participants with an indication of billed hearing services. Members of the Cohort 2 were more likely that those in Cohort 1 to have a number of chronic conditions. For example, 63% of Cohort 2 and 13% of Cohort 1 have a hypertension diagnosis (Table 1) . Subcohort 3, a subgroup of the Medicare matched cohort, were slightly older (mean 79), more likely to be female (73%), and more racially diverse (63% white, 37% non-white) than Cohort 2. This subgroup had the highest proportion of chronic conditions, with a particularly high proportion of dementia diagnoses (>13%) ( Table 1 ). The propensity score matching within Cohorts 1 and 2 produced very similar groups at baseline. Subcohort 3, although not formally matched, have similar baseline characteristics between the HL diagnosed and not diagnosed comparison groups.
Total unadjusted mean hospital payments were consistently highest in the HL group and lowest in the no-HL group in each of the 3 cohorts, with the HL group with hearing services falling between the 2 (Table 2) . When comparing total 18-month healthcare payments of the 3 cohorts, Cohort 1 had the highest (average $21,164 per person), followed by Subcohort 3 ($18,193), and then ($13,129) ( Table 2 ).
Adjusted models of matched cohorts showed significantly higher healthcare payments for individuals with a diagnosis of HL during follow-up than for those with no diagnosis of HL (Table 3 ). The subgroup of individuals with a diagnosis of HL who received hearing services had significantly lower overall mean costs ($1,431 lower for Cohort 1, $1,648 lower for Cohort 2, $3,431 lower for Figure 1 ). Higher hospital and outpatient costs may have led to these differences (Table 2) .
DISCUSSION
The objective of this study was to compare average healthcare costs in U.S. older adults with and without HL. We used data from two sources: Medicare billing data for individuals aged 65 and older with supplementary private health insurance and a 5% random sample of Medicare data that the Centers for Medicare and Medicaid Services selected as a representative limited sample of all U.S. Medicare beneficiaries. The use of these data sources enabled us to examine healthcare costs for Medicare beneficiaries with substantially different levels of financial resources. The data sets have different benefits and limitations. The Medicare plus supplemental private insurance (Cohort 1) dataset contains all Medicare bills, including bills for prescription payments but does not include race. The Medicare 5% (Cohort 2) sample does not include prescription payments but includes race and allowed us to examine individuals with dual Medicare and Medicaid eligibility (Subcohort 3), a subgroup of individuals who meet Medicaid income eligibility criteria. Within the 3 datasets defined according to insurance type, we observed similar differences in mean cost for the 18-month observation period; individuals with untreated HL had the highest cost, followed by those with treated HL, and then those without HL. We also observed a consistent cost pattern across the 3 comparison groups in all 3 insurance cohorts. Cohort 1 had the highest mean cost, in part because this dataset included the cost of all prescription medications, and Cohort 2 had the lowest cost.
The primary findings of this study of 21.5% higher (Cohort 1) 18-month costs in older adults with Medicare and supplemental insurance with a diagnosis of HL than in those without a diagnosis of HL are similar to the findings of our recently published study in a sample of adults aged 55 to 64 in whom we found 33% greater costs in individuals with HL compared with a matched group without HL. 19 Although the cost difference in the older group reported here is less than observed in the younger sample, the same pattern of decreasing costs between those with HL (highest costs) and those with HL and hearing services (middle costs) compared to those with no indication of HL (lowest costs) remained consistent. A previous study reported $392 (95% confidence interval (CI)5$277-513) in excess annual medical expenditures for individuals with HL in an analysis of Medical Expenditure Panel Survey data from 2000 to 2012. 28 Our annualized expenditure differences associated with HL were $2,391, but the previous analysis depended on the combination of 12 years of data and a much smaller sample that could not be matched at baseline, so it is possible that unmeasured differences in comorbid conditions and age is obscuring expenditure differences due to reported HL. In a systematic review of the economic effects of HL, another study found consistently higher costs and expenditures for individuals with HL, with a very high cost of forgone earnings and lifetime expenditures. 29 Most studies focus on total cost to society and lifetime effects of HL on earnings, although one study found mean expenditures of $1,012 for hearing services in the first year of reported HL, which is similar our finding of $1,296 of the added cost of hearing services. 30 Although these new findings are an important early step in providing the evidence needed to raise awareness of HL from an annoyance or a normal consequence of aging to a public health concern, there are inherent limitations to the use of retrospective billing data. The use of administrative claims to ascertain diagnoses and identify resource use and costs with complete accuracy is difficult, because these data are collected not for clinical research but to determine healthcare payments. 31 In addition, there are known variations in coding practices, 31 which are likely to change over time and differ between institutional settings. Perhaps most importantly in this study, these data lacked clinical information, including confirmatory diagnosis of HL and use of hearing services. Because limited reimbursement rules of insurers, including Medicare and private insurance, govern hearing testing and hearing services, there is likely to be significant undercoding of diagnoses and services billed, 31 so we might expect to find only a certain group of individuals with hearing services on their Medicare bills. These individuals may differ in systematic ways from others who receiving hearing health care but are paying out of pocket or the larger number of individuals with hearing deficits who do not seek care. Examination of marginal cost differences between 2 populations using the same data, using propensity methods, reduces the likelihood of a significant confounding effect on internal validity because many of these limitations related to administrative data will be equal in both groups, resulting in valid differences.
Propensity score methods in combination with wellspecified, controlled outcomes modeling help to reduce selection bias and confounding due to imbalances in measured baseline covariates between the comparison groups, but these methods cannot control for bias that might occur because of unmeasured confounders, unless unmeasured confounders are correlated with those that were measured. 32 The degree to which unmeasured factors may influence the results of the study can be estimated using sensitivity analyses. 27, 33 The results of this study appear to be insensitive to unmeasured confounders when we examine the case of the primary difference in cost between individuals with and without HL in Cohort 1 ($3,587; the smallest difference between the three comparators). If an unmeasured confounder increased average cost by $4,396, which is equal to the largest predictor in the outcome model, having chronic renal failure, and if the prevalence of an unmeasured confounder, such as high level of treatment-seeking behavior, is 10% higher in the HL group than in those without HL, the estimated unbiased difference between these groups would be $3,147 (95% CI5$3,118-3,306). Even if we were to change the prevalence assumption to an unlikely 60% difference between groups, the estimated unbiased difference in cost between individuals with and without HL would be $949 (95% CI5$920-1,108). Thus, it seems unlikely that an unmeasured confounding variable could have an effect on the outcome large enough to invalidate the qualitative conclusion that 18-month healthcare costs are substantially higher in individuals with HL than in those without.
CONCLUSION
Older adults with a diagnosis of HL have substantially higher healthcare costs than a matched comparison group of individuals without a HL diagnosis regardless of type of insurance or indication of use of hearing healthcare services. The lack of audiometry confirmation of HL and our inability to differentiate between successful and unsuccessful HL interventions limit this study, although after propensity score matching and covariate adjustment, we observed more than 20% higher payments over an 18-month period for a group of insured individuals with HL. This finding indicates that negative health-related effects of HL may increase healthcare use unrelated to HL. There is currently no Medicare coverage for hearing aids or for most hearing healthcare services; private insurance coverage and Medicaid are limited, and Medicaid coverage varies widely according to state. Future studies are needed to determine whether greater coverage for hearing healthcare or use of hearing aids results in cost savings for Medicare and other insurers in potentially avoidable healthcare use and better quality of life.
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